NIR-ICG Imaging for Rheumatoid Arthritis
Trial Summary
Will I have to stop taking my current medications?
The trial does not specify if you need to stop your current medications. However, if you have established RA, you must be on a stable dose of certain medications for at least 8 weeks before joining.
What data supports the effectiveness of the treatment Near InfraRed Indocyanine Green fluorescence imaging (NIR-ICG) for rheumatoid arthritis?
Is NIR-ICG imaging safe for humans?
How does NIR-ICG imaging differ from other treatments for rheumatoid arthritis?
What is the purpose of this trial?
Lymphatic transport was previously examined by these investigators using Near InfraRed Indocyanine Green fluorescence imaging (NIR-ICG) of the upper extremities. They established reliable and reproducible methodologies in RA patients. The purpose of this phase 2 pilot is to study RA disease progression and effectiveness as well as the mechanism of action of clinical interventions using established NIR-ICG methodologies in previous studies.
Research Team
Christopher Ritchlin, MD, MPH
Principal Investigator
University of Rochester
Eligibility Criteria
This trial is for adults with early or established Rheumatoid Arthritis (RA) who meet specific criteria, including being on a stable dose of certain RA medications. They must have active joint inflammation in their hands confirmed by ultrasound and not be pregnant or have other systemic disorders that could affect the study.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Baseline Imaging
Participants receive ICG injections and undergo NIR-ICG imaging at baseline prior to the start of anti-TNF therapy
Treatment and Imaging
Participants receive anti-TNF therapy and undergo NIR-ICG imaging at 16 weeks and 1 year post-treatment
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Indocyanine green
- MultiSpectral Imaging System
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Rochester
Lead Sponsor
National Institutes of Health (NIH)
Collaborator
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Collaborator